Allergan plc (NYSE:AGN) Position Boosted by EP Wealth Advisors LLC

EP Wealth Advisors LLC increased its position in shares of Allergan plc (NYSE:AGN) by 47.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,830 shares of the company’s stock after acquiring an additional 14,101 shares during the period. EP Wealth Advisors LLC’s holdings in Allergan were worth $7,376,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the stock. Prosight Management LP acquired a new stake in Allergan during the fourth quarter worth about $16,031,000. Tower Research Capital LLC TRC lifted its stake in Allergan by 479.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,768 shares of the company’s stock worth $289,000 after purchasing an additional 1,463 shares during the period. Canyon Capital Advisors LLC lifted its stake in Allergan by 248.4% during the fourth quarter. Canyon Capital Advisors LLC now owns 501,494 shares of the company’s stock worth $82,034,000 after purchasing an additional 357,559 shares during the period. Vantage Financial Partners Ltd. Inc. lifted its stake in Allergan by 23.8% during the fourth quarter. Vantage Financial Partners Ltd. Inc. now owns 6,250 shares of the company’s stock worth $1,018,000 after purchasing an additional 1,200 shares during the period. Finally, Stephens Inc. AR raised its stake in shares of Allergan by 24.2% in the first quarter. Stephens Inc. AR now owns 30,566 shares of the company’s stock valued at $5,144,000 after acquiring an additional 5,960 shares during the last quarter. Institutional investors and hedge funds own 79.16% of the company’s stock.

A number of research analysts have recently issued reports on the stock. Credit Suisse Group set a $213.00 target price on shares of Allergan and gave the company a “buy” rating in a research note on Tuesday, June 12th. Bank of America raised their price target on shares of Allergan from $209.00 to $213.00 and gave the company a “buy” rating in a report on Tuesday, June 12th. Wells Fargo & Co reissued a “buy” rating on shares of Allergan in a report on Monday, June 11th. Cantor Fitzgerald set a $180.00 price target on shares of Allergan and gave the company a “hold” rating in a report on Monday, June 11th. Finally, Mizuho boosted their price objective on shares of Allergan from $150.00 to $176.00 and gave the company a “neutral” rating in a research report on Monday, June 11th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the stock. Allergan has a consensus rating of “Hold” and an average target price of $212.15.



In other news, EVP William Meury sold 24,425 shares of Allergan stock in a transaction dated Thursday, May 17th. The shares were sold at an average price of $154.59, for a total value of $3,775,860.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.37% of the stock is owned by company insiders.

Shares of NYSE AGN traded up $4.32 during mid-day trading on Wednesday, reaching $177.37. 62,669 shares of the company’s stock traded hands, compared to its average volume of 2,714,412. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.10 and a quick ratio of 0.94. Allergan plc has a 1-year low of $142.81 and a 1-year high of $256.80. The stock has a market capitalization of $58.22 billion, a P/E ratio of 10.70, a P/E/G ratio of 1.21 and a beta of 1.12.

Allergan (NYSE:AGN) last released its quarterly earnings results on Monday, April 30th. The company reported $3.74 earnings per share for the quarter, beating analysts’ consensus estimates of $3.36 by $0.38. The company had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.59 billion. Allergan had a negative net margin of 11.94% and a positive return on equity of 8.53%. The firm’s revenue was up 2.8% on a year-over-year basis. During the same period last year, the firm earned $3.35 earnings per share. equities research analysts anticipate that Allergan plc will post 16.06 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, June 15th. Stockholders of record on Friday, May 18th were paid a $0.72 dividend. The ex-dividend date was Thursday, May 17th. This represents a $2.88 annualized dividend and a dividend yield of 1.62%. Allergan’s payout ratio is 17.61%.

Allergan Profile

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply